title: Microencapsulation of mildronate in biodegradable and non-biodegradable polymers.
abstract: The extremely high hygroscopicity (solubility in water ≥2 g/ml) of the pharmaceutical preparation mildronate defines specific requirements to both packaging material and storage conditions. To overcome the above mentioned inconveniences, microencapsulated form of mildronate was developed using polystyrene (PS) and poly (lactic acid) (PLA) as watertight coating materials. Drug/polymer interaction as well as influence of the microencapsulation process variables on microparticle properties was studied in detail. Water-in-oil-in-water double emulsion technique was adapted and applied for the preparation of PS/mildronate microparticles with total drug load up to 77 %wt and PLA/mildronate microparticles with total drug load up to 80 %wt. The repeatability of the microencapsulation process was ±4% and the encapsulation efficiency of the active ingredient reached 60 %wt. The drug release kinetics from the obtained microparticles was evaluated and it was found that drug release in vivo could be successfully sustained if polystyrene matrix has been used.
authors.affiliation: Rudolfs Cimdins Riga Biomaterials Innovations and Development Centre of Riga Technical University , Pulka 3/3, LV-1007, Riga , Latvia .
authors.forename: Dagnija
authors.initials: D
authors.lastname: Loca
authors.forename: Eduards
authors.initials: E
authors.lastname: Sevostjanovs
authors.forename: Marina
authors.initials: M
authors.lastname: Makrecka
authors.forename: Olga
authors.initials: O
authors.lastname: Zharkova-Malkova
authors.forename: Liga
authors.initials: L
authors.lastname: Berzina-Cimdina
authors.forename: Velta
authors.initials: V
authors.lastname: Tupureina
authors.forename: Marina
authors.initials: M
authors.lastname: Sokolova
mesh_terms: D000818:Animals; D002214:Capsules; D002317:Cardiovascular Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D007700:Kinetics; D019344:Lactic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D008763:Methylhydrazines / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011091:Polyesters; D011108:Polymers / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011137:Polystyrenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits
chemical_list: D002214:Capsules; D002317:Cardiovascular Agents; D008763:Methylhydrazines; D011091:Polyesters; D011108:Polymers; D011137:Polystyrenes; D019344:Lactic Acid; C033616:poly(lactide); C050147:3-(2,2,2-trimethylhydrazine)propionate